Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
GHR Antibody (N-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | P10912 |
|---|---|
| Clone Names | 100617223 |
| Gene ID | 2690 |
|---|---|
| Other Names | Growth hormone receptor, GH receptor, Somatotropin receptor, Growth hormone-binding protein, GH-binding protein, GHBP, Serum-binding protein, GHR |
| Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
| Name | GHR |
|---|---|
| Function | Receptor for pituitary gland growth hormone involved in regulating postnatal body growth. On ligand binding, couples to the JAK2/STAT5 pathway (By similarity). Isoform 2 up-regulates the production of GHBP and acts as a negative inhibitor of GH signaling. |
| Cellular Location | Cell membrane; Single-pass type I membrane protein. Note=On growth hormone binding, GHR is ubiquitinated, internalized, down-regulated and transported into a degradative or non- degradative pathway. [Growth hormone-binding protein]: Secreted. Note=Complexed to a substantial fraction of circulating GH |
| Tissue Location | Expressed in various tissues with high expression in liver and skeletal muscle. Isoform 4 is predominantly expressed in kidney, bladder, adrenal gland and brain stem. Isoform 1 expression in placenta is predominant in chorion and decidua. Isoform 4 is highly expressed in placental villi. Isoform 2 is expressed in lung, stomach and muscle. Low levels in liver |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes a protein that is a transmembranereceptor for growth hormone. Binding of growth hormone to thereceptor leads to receptor dimerization and the activation of anintra- and intercellular signal transduction pathway leading togrowth. A common alternate allele of this gene, called GHRd3, lacksexon three and has been well-characterized. Mutations in this genehave been associated with Laron syndrome, also known as the growthhormone insensitivity syndrome (GHIS), a disorder characterized byshort stature. Other splice variants, including one encoding asoluble form of the protein (GHRtr), have been observed but havenot been thoroughly characterized. In humans and rabbits, but notrodents, growth hormone binding protein (GHBP) is generated byproteolytic cleavage of the extracellular ligand-binding domainfrom the mature growth hormone receptor protein. The preciselocation of this cleavage site has not been determined for thehuman protein.
References
Canzian, F., et al. Hum. Mol. Genet. 19(19):3873-3884(2010)Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Giavoli, C., et al. Eur. J. Endocrinol. 163(3):361-368(2010)Alvarez-Nava, F., et al. J. Pediatr. Endocrinol. Metab. 23(8):773-782(2010)Lisitskaia, K.V., et al. Mol. Gen. Mikrobiol. Virusol. 2, 34-37 (2010) :
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Shipping Information
